Bausch Health vs NVIDIA: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Bausch Health and NVIDIA side by side

1. 1959Bausch Health

   Milan Panic founds ICN Pharmaceuticals

   Milan Panic, a Yugoslav immigrant to California, founded ICN Pharmaceuticals in 1959 and ran it for four decades. ICN is the predecessor of Valeant Pharmaceuticals and of today's Bausch Health.

2. 1993NVIDIA

   Founding in Santa Clara

   Jensen Huang, Chris Malachowsky, and Curtis Priem founded NVIDIA on April 5, 1993, with a focus on 3D graphics for gaming and multimedia. The founding set the company on a parallel-processing path long before AI infrastructure became the main market.

3. 1994Bausch Health

   Biovail Corporation International formed in Canada

   On March 29, 1994 Eugene Melnyk consolidated his Canadian drug-delivery business by amalgamating Trimel Corporation with its subsidiary to create Biovail Corporation International, the legal entity that files today as Bausch Health Companies Inc.

4. 1999NVIDIA

   GPU Category Defined

   NVIDIA introduced the graphics processing unit concept in 1999. The milestone mattered because it framed graphics hardware as a specialized processor, a technical idea that later carried into accelerated computing and AI workloads.

5. 2003Bausch Health

   ICN renames itself Valeant Pharmaceuticals

   ICN Pharmaceuticals, then based in Costa Mesa, California, took the Valeant Pharmaceuticals name in November 2003 to distance itself from the governance fights of the Panic era.

6. 2006NVIDIA

   CUDA Opens GPUs to General Computing

   CUDA opened GPU parallel processing to scientists, researchers, and developers outside graphics. It became the software foundation that made NVIDIA hardware useful for machine learning, simulation, and other compute-heavy workloads.

7. 2008Bausch Health

   J. Michael Pearson becomes chief executive

   Valeant appointed former McKinsey director J. Michael Pearson as chief executive effective February 1, 2008, succeeding Timothy C. Tyson. Pearson replaced internal research spending with debt-funded acquisitions of marketed drugs.

8. 2010Bausch Health

   Biovail and Valeant complete their merger

   The merger of Biovail Corporation and Valeant Pharmaceuticals International closed on September 28, 2010. The combined company kept the Valeant name and Pearson as chief executive but was incorporated in Canada.

9. 2011Bausch Health

   Ortho Dermatologics bought from Johnson and Johnson

   Valeant agreed to acquire the U.S. Ortho Dermatologics assets from Janssen Pharmaceuticals, a Johnson and Johnson company, for about $345M in cash, building the dermatology franchise.

10. 2012NVIDIA

    AlexNet Shows GPU Value for Deep Learning

    The AlexNet breakthrough used NVIDIA GPUs to win the ImageNet competition. The event helped convince researchers and engineers that GPUs could accelerate neural-network training at a scale CPUs could not match.

11. 2013Bausch Health

    Bausch + Lomb acquired for $8.7 billion

    Valeant agreed in May 2013 to buy eye-health company Bausch + Lomb from Warburg Pincus for $8.7B in cash, adding contact lenses, lens care, ophthalmic drugs and surgical devices.

12. 2015Bausch Health

    Salix acquisition closes at about $11.1 billion

    Valeant completed its tender offer for Salix Pharmaceuticals on April 1, 2015 at $173 per share, about $11.1B in equity value and roughly $15.8B including debt, gaining the Xifaxan franchise.

13. 2015Bausch Health

    Drug pricing and Philidor scandal breaks

    Congressional investigators pressed Valeant over 525% and 212% increases on the heart drugs Isuprel and Nitropress, bought in February 2015, and over its undisclosed ties to the Philidor mail-order pharmacy.

14. 2016Bausch Health

    Joseph Papa replaces Pearson as chief executive

    Valeant named Perrigo chief executive Joseph C. Papa as chairman and CEO on April 25, 2016, and he took over in early May 2016 with about $30B of debt outstanding.

15. 2016NVIDIA

    DGX-1 AI Supercomputer

    Nvidia introduced the DGX-1 deep-learning supercomputer in 2016, its first system built specifically for artificial intelligence.

16. 2017Bausch Health

    Skincare brands and Dendreon sold to cut debt

    Valeant sold the CeraVe, AcneFree and AMBI skincare brands to L'Oreal for about $1.3B and the Dendreon cancer unit to China's Sanpower Group for about $820M, using the proceeds to repay debt.

17. 2018Bausch Health

    Company renamed Bausch Health Companies Inc.

    The name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. was completed on July 13, 2018, and the shares began trading as BHC on the NYSE and TSX on July 16, 2018.

18. 2018NVIDIA

    RTX Brings Real-Time Ray Tracing to Graphics

    NVIDIA RTX brought real-time ray tracing into the company's graphics roadmap. The product line kept gaming and professional visualization tied to AI-enhanced rendering while Data Center was becoming more important.

19. 2020Bausch Health

    SEC settlement closes the Philidor accounting case

    On July 31, 2020 Bausch Health agreed to pay a $45M civil penalty to settle SEC charges of improper revenue recognition and misleading disclosures tied to Philidor. Former chief executive J. Michael Pearson and two other executives also settled.

20. 2020NVIDIA

    Mellanox Acquisition Adds Networking

    NVIDIA completed the Mellanox acquisition for about $7 billion. The deal mattered because large AI and high-performance-computing clusters depend on fast networking between accelerators, not only on individual GPU speed.

21. 2022Bausch Health

    Bausch + Lomb listed on the NYSE and TSX

    Bausch + Lomb common stock began trading under the ticker BLCO on May 6, 2022, and a Bausch Health subsidiary sold 35,000,000 Bausch + Lomb shares in the offering. Bausch Health retained about 88% of the eye-health company and still consolidates it. Thomas J.

22. 2022NVIDIA

    Arm Acquisition Terminated

    NVIDIA and SoftBank terminated the proposed Arm acquisition because of significant regulatory challenges. The failed deal showed how closely governments watch control points in semiconductor architecture.

23. 2022NVIDIA

    Hopper H100 Announced

    Nvidia announced the Hopper-architecture H100 data-center GPU in March 2022.

24. 2023NVIDIA

    Grace CPU Enters Data Center Roadmap

    NVIDIA introduced its first data-center CPU, Grace, for large-scale AI and high-performance computing. The milestone expanded the platform from GPUs and networking into CPU-GPU system design.

25. 2024NVIDIA

    Blackwell Architecture Launched

    NVIDIA launched Blackwell as a data-center-scale architecture combining GPUs, CPUs, DPUs, interconnects, switch chips, systems, and networking adapters. The architecture became central to FY2026 Data Center demand.

26. 2025Bausch Health

    DURECT acquired and record annual revenue reported

    Bausch Health closed the DURECT acquisition on September 11, 2025 for about $63M upfront, completed Solta Medical's Chinese aesthetics distribution purchase on December 1, 2025, and reported FY2025 revenue of $10.266B, up 7%, with net income attributable to Ba…

27. 2026Bausch Health

    RED-C trials miss endpoints and trigger a $1.4 billion charge

    In January 2026 the two Phase 3 RED-C trials of amorphous-rifaximin soluble solid dispersion for primary prevention of hepatic encephalopathy missed their primary endpoints.

28. 2026Bausch Health

    Second-quarter 2026 revenue of $2.85 billion and raised guidance

    Bausch Health reported second-quarter 2026 revenue of $2.85B, up 13%, net income attributable to Bausch Health of $258M and adjusted EBITDA of $1.075B, and raised its full-year 2026 revenue, adjusted EBITDA and cash flow guidance.

29. 2026NVIDIA

    $215.9B FY2026 Revenue

    NVIDIA reported $215.9 billion of FY2026 revenue, $193.7 billion of Data Center revenue, and $120.1 billion of net income. The result showed how far AI infrastructure had moved the company beyond its original PC graphics market.

Acquisitions

Questions about Bausch Health vs NVIDIA